All articles tagged with #obesity biotech
Originally Published 2 months ago — by Seeking Alpha
Pfizer has matched Novo Nordisk's bid for the obesity biotech Metsera amid a fierce takeover battle, highlighting the competitive interest in the obesity treatment sector.
Originally Published 2 months ago — by Financial Times
Pfizer has matched Novo Nordisk's bid for the obesity biotech Metsera amid a fierce takeover competition, highlighting the high stakes in the biotech industry.
Originally Published 2 months ago — by CNBC
Pfizer has filed a second lawsuit against Novo Nordisk and Metsera, accusing Novo Nordisk of anti-competitive practices in its bid to acquire Metsera, a biotech with potential obesity treatments, amidst a fierce bidding war that could reshape the weight loss drug market.
Originally Published 2 months ago — by Reuters
Pfizer is considering leveraging its political connections, particularly with President Trump, to counter Novo Nordisk's bid for obesity biotech firm Metsera, amid concerns over market dominance and antitrust issues, as Pfizer faces setbacks in its obesity drug development and seeks to strengthen its market position.